Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe thigh is one of three licensed injection sites for Wegovy, and for many people it becomes their preferred spot. It is easy to reach, offers a decent amount of fatty tissue, and requires no help from another person. Wegovy (semaglutide) is a prescription-only medicine for weight management, so which site works best for you is something to settle with your prescriber — but here is what the evidence and clinical guidance actually say about using the thigh.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A common worry circulating on forums is that injecting Wegovy into the thigh delivers less of the drug than the abdomen does, so results suffer. The evidence does not support this as a clinical concern for semaglutide. Subcutaneous absorption can vary slightly between sites in pharmacokinetic studies, but the licensed prescribing information for Wegovy lists the outer thigh as an equivalent site alongside the abdomen and upper arm. No clinical guidance currently recommends one over the others for efficacy reasons.
If you have seen claims that the stomach is the only 'real' site for semaglutide, they are not grounded in the approved product information. The NHS medicines page for semaglutide confirms all three sites are appropriate. What does matter is that the injection reaches the subcutaneous fat layer (the soft tissue just beneath the skin) rather than muscle. Getting the technique right is more important than the postcode on your body where you do it.
If you are curious how site choice compares in practice, our page on whether to use the stomach or thigh for Wegovy walks through the practical differences in more detail.
The outer thigh is the recommended area, running roughly from the top of the knee to the hip on the front-outer surface of the leg. Avoid the inner thigh, the skin there tends to be thinner, more sensitive, and closer to major blood vessels. There is a full discussion of why the inner thigh is generally avoided if you want the detail.
Sit comfortably with your leg relaxed before you begin. Clean the skin with an alcohol swab and let it dry fully, injecting through wet skin can sting more and introduces moisture to the site. Hold the pen at a 90-degree angle, press the cap firmly against the skin until it clicks, and keep it held in place for the count recommended in your Patient Information Leaflet. Pressing too lightly is one of the most common reasons people get incomplete injections.
A practical habit many people find useful: keep your pen at the back of the fridge door where it is easy to see, and rotate the physical side of the fridge sticker each week as a reminder to switch thighs. Left thigh one week, right thigh the next, and then cycle to the abdomen or upper arm to give both thighs a rest. The step-by-step guide to the Wegovy thigh injection covers the full technique if you want to go deeper on any of these points.
Lipohypertrophy (a hardening or thickening of the fatty tissue under the skin) is a well-documented consequence of repeatedly injecting into exactly the same spot. It is not dangerous in itself, but drug absorption from those thickened areas can become unreliable, which is a real problem with a medicine taken once weekly. The NHS semaglutide guidance and the approved SmPC both recommend rotating sites systematically.
Practical rotation means varying not just which body zone you use (thigh, abdomen, arm) but also the precise spot within that zone week to week. On the thigh, aim for a different small area (a centimetre or two from the previous spot) rather than always hitting the same patch of skin. Mild redness or a small bump after an injection usually settles within a day or two and is not a reason to stop. If you notice persistent lumps, unusual bruising or skin changes, mention them at your next prescriber review.
For a broader look at how Wegovy works and what the maintenance doses involve, the Wegovy overview covers the full clinical picture, including the titration schedule up to 2.4mg. If you are weighing up treatment options more generally, our weight-loss treatment page sets out what is available and how each medicine is approached at nume.
Some people find the thigh uncomfortable simply because of lower body fat distribution, or because the skin in that area is more sensitive around dose increases. That is not unusual. The abdomen tends to have more accessible subcutaneous tissue for many people, and the upper arm (used non-dominant side, outer surface) is a practical option for those who find both thigh and abdomen awkward.
People who carry very little body fat in the thigh area, or who experience consistent bruising there, should discuss an alternative site with their prescriber. The evidence on whether site affects how well Wegovy works is worth reading if this question is driving your decision. And if you are thinking about how dosing progresses over time, the page on how high the Wegovy dose goes explains the titration pathway through to the maintenance dose.
Wegovy is a prescription-only medicine. A prescriber assesses your full health picture (including any skin conditions, previous injection-site reactions or anatomical factors) before making recommendations about technique. If you are considering starting treatment, check your eligibility with a free consultation and a GPhC-registered prescriber at nume will review your application the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.